دورية أكاديمية
Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries.
| العنوان: | Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. |
|---|---|
| المؤلفون: | Lamba N; Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts, USA.; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA., Cagney DN; Mater Private Hospital, Dublin, Ireland., Catalano PJ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Elhalawani H; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA., Haas-Kogan DA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Wagle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Lin NU; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Aizer AA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA., Tanguturi S; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA. |
| المصدر: | Neuro-oncology [Neuro Oncol] 2023 May 04; Vol. 25 (5), pp. 973-983. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2010- : Oxford : Oxford University Press Original Publication: 1999-<2002> : Charlottesville, VA : Carden Jennings Pub., |
| مواضيع طبية MeSH: | Breast Neoplasms*/epidemiology , Breast Neoplasms*/pathology , Meningeal Neoplasms* , Brain Neoplasms*, Humans ; Female ; Incidence ; Prognosis ; Retrospective Studies |
| مستخلص: | Background: Leptomeningeal disease (LMD) is a relatively uncommon manifestation of advanced cancer. Patients with LMD carry a poor prognosis and often decline rapidly, complicating inclusion in clinical trials. Identification of LMD subsets of greater incidence and more favorable prognosis might facilitate dedicated clinical trials in the future. We hypothesized that patients with breast cancer may represent such a population and sought to assess the relative incidence and prognosis of LMD secondary to breast vs. non-breast primaries. Methods: We identified 2411 patients with intracranial metastases secondary to breast (N = 501) and non-breast (N = 1910) primaries at Brigham and Women's Hospital/Dana-Farber Cancer Institute between 1996 and 2020, of whom 112 presented with and an additional 161 subsequently developed LMD. A log-rank test and Cox modeling were used to compare outcomes in patients with breast vs. non-breast primaries. Results: Among patients with newly diagnosed intracranial disease, the incidence proportion of concurrent LMD was 11.4% vs. 2.9% among patients with breast vs. non-breast primaries (P < .001). Development of LMD among initially LMD-naïve patients was also more common among patients with breast vs. non-breast primaries (HR = 1.49 [1.05-2.11], P = .03). Patients with LMD secondary to breast vs. non-breast primaries displayed lower all-cause mortality (HR 0.70 [0.52-0.93], P = .01; median survival: 5.2 vs. 2.4 months, respectively), with a greater numerical difference observed in patients with LMD at intracranial involvement (7.4 vs. 2.6 months, respectively). Conclusions: Patients with breast cancer and LMD may represent an ideal population for clinical trials given the higher incidence and potentially more favorable prognosis seen in this population. (© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| References: | J Neurooncol. 2011 Sep;104(2):565-72. (PMID: 21234642) Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):579-586. (PMID: 31605786) JAMA. 2006 Jun 7;295(21):2483-91. (PMID: 16757720) Curr Cancer Ther Rev. 2011 Nov;7(4):319-327. (PMID: 23251128) Radiother Oncol. 2016 Nov;121(2):217-224. (PMID: 27793446) Neuro Oncol. 2014 Sep;16(9):1176-85. (PMID: 24867803) Cancer. 1982 Feb 15;49(4):759-72. (PMID: 6895713) Neurooncol Adv. 2021 Dec 04;3(1):vdab181. (PMID: 34993483) JAMA Oncol. 2018 Jul 1;4(7):1001-1003. (PMID: 29799956) JAMA Oncol. 2019 May 01;5(5):703-709. (PMID: 30844036) J Clin Oncol. 2004 Aug 15;22(16):3302-8. (PMID: 15310773) Oncotarget. 2017 Aug 16;8(42):73312-73328. (PMID: 29069871) Curr Opin Oncol. 2010 Nov;22(6):627-35. (PMID: 20689429) Neuro Oncol. 2021 Sep 1;23(9):1447-1456. (PMID: 33908612) JAMA. 1998 Nov 4;280(17):1485-9. (PMID: 9809728) Neuro Oncol. 2019 May 6;21(5):571-584. (PMID: 30668804) Cancer. 2007 Dec 15;110(12):2640-7. (PMID: 17960791) JAMA. 2016 Jul 26;316(4):401-409. (PMID: 27458945) J Neurooncol. 2012 Jan;106(2):303-13. (PMID: 21938531) Breast J. 2019 Nov;25(6):1117-1125. (PMID: 31286623) Neuro Oncol. 2020 Jun 9;22(6):757-772. (PMID: 32048719) Cancer. 1994 Dec 15;74(12):3135-41. (PMID: 7982179) Neurology. 2010 May 4;74(18):1449-54. (PMID: 20439847) Crit Rev Oncol Hematol. 2019 Mar;135:85-94. (PMID: 30819451) Neurosurg Clin N Am. 2011 Jan;22(1):67-78, vii. (PMID: 21109151) J Neurol Sci. 2004 Aug 30;223(2):167-78. (PMID: 15337619) Ann Oncol. 2010 Nov;21(11):2183-2187. (PMID: 20430906) Clin Cancer Res. 2007 Mar 15;13(6):1648-55. (PMID: 17363517) J Neurooncol. 2007 Aug;84(1):57-62. (PMID: 17310266) Cancer. 2008 Nov 15;113(10):2638-45. (PMID: 18833576) ESMO Open. 2021 Jun;6(3):100150. (PMID: 33984675) J Clin Oncol. 2011 Jan 10;29(2):134-41. (PMID: 21041710) Lancet Oncol. 2017 Aug;18(8):1049-1060. (PMID: 28687377) Cancer. 1991 Mar 15;67(6):1685-95. (PMID: 2001559) J Cancer Res Clin Oncol. 2010 Nov;136(11):1729-35. (PMID: 20204406) |
| فهرسة مساهمة: | Keywords: brain metastases; breast cancer; leptomeningeal disease |
| تواريخ الأحداث: | Date Created: 20221111 Date Completed: 20230505 Latest Revision: 20231112 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10158280 |
| DOI: | 10.1093/neuonc/noac249 |
| PMID: | 36367837 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!